Clarus Therapeutics withdraws IPO
This article was originally published in Scrip
Executive Summary
Clarus Therapeutics, based in Northbrook, Illinois, has reportedly withdrawn its plans for an initial public offering citing poor market conditions. The company, however, appears to be moving forward with its pivotal Phase III trial of its investigational oral testosterone product OriTex to treat hypogonadal men.